New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer.
Dr Blank has served in the role in a temporary capacity since January this year and now takes on the post permanently.
He brings over 25 years of industry experience to Acorda, and has held senior leadership positions at Altus Pharmaceuticals, Herantis Pharma and Laurantis Pharma.
Prior to this, Dr Blank worked at Boehringer Ingelheim, first as its global head for regulatory affairs before serving as its chief medical officer between 2001 and 2006.
Dr Ron Cohen, president and chief executive of Acorda, said: “I am delighted that Burkhard has joined Acorda as our chief medical officer.
“Burkhard brings to Acorda an impressive record of successful drug development and approved NDAs. This will benefit Acorda’s entire pipeline, including our late-stage development programs, CVT-301 and tozadenant for Parkinson’s disease.”